Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GNET study of filgrastim for severe bullous drug allergy presenting as Stevens-Johnson syndrome or toxic epidermal necrolysis
2020-003544-83Phase 2Active
- Sponsor
- Hospices Civils de Lyon
- Start
- Jan 2021
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial in Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) comparing Filgrastim + reference symptomatic care with Placebo + reference symptomatic care (2 arms). Primary endpoint: Cessation of progression of skin detachment at day 5. Started Jan 2021; status: active.
02
Drugs
filgrastim
03
Conditions
Stevens-Johnson syndrome (SJS)toxic epidermal necrolysis (TEN)
Beyond the preview
Go deeper on 2020-003544-83.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003544-83.